OraSure Taps Former J&J Exec For CEO Post; OraQuick Obtains CLIA Waiver
This article was originally published in The Gray Sheet
Executive Summary
Newly appointed OraSure President & CEO Douglas Michels will rely on international marketing experience gained at Ortho-Clinical Diagnostics to build a rapid infectious disease test presence outside the U.S
You may also be interested in...
OraSure Targets HIV-1/2, Hepatitis Tests To Grow Business To $250 Mil.
OraSure is setting its sights on obtaining FDA approval of an OraQuick HIV-2 rapid oral fluid test, as well as licensing rights from Bio-Rad for the antibody patents, following approval of an HIV-1 version March 26
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.